Magnephy Request a study

Applications

What we run for your program.

Validated assays we run today, and specialised assays we set up on request. Each assay is built on the same workflow: tissue clearing, super-resolution imaging and AI segmentation.

Ready, validated assays

Assays we run today.

Raw super-resolution micrograph of kidney foot processes fading into its AI segmentation, each structure individually colour-labelled. Magnephy in-house.

Quantitative kidney pathology

Podocyte morphology, basement membrane alterations and immune deposition, AI-quantified across tissue volumes. Applicable to any kidney disease, including CKD, FSGS, IgA nephropathy, Diabetic nephropathy, and Lupus nephritis. Works with FFPE, fresh-frozen, and fixed pre-clinical and clinical samples.

What you receive

  • Per-glomerulus and per-cohort metrics
  • 3D visualisations of structure and disease state
  • Reproducible across timepoints and treatment arms
Multi-colour overview of a kidney biopsy section, showing tissue context for drug-target localisation. Magnephy in-house imaging.

Antibody-therapeutic biodistribution

Drug, target, and structure resolved in the same volume, at 30 nm. Localisation and colocalisation at the subcellular level, in 3D.

What you receive

  • Per-cell, per-region drug-target colocalisation maps
  • Structural context for biodistribution and off-target information
  • Comparable across dose levels and candidates
Multiplex view of a glomerulus with multi-channel markers. Magnephy in-house imaging.

Multiplex biomarker readouts

Multi-channel intensity and subcellular spatial distributions, AI-quantified across 3D volumes. Reproducible cohort-level comparisons of the biomarkers that matter to you.

What you receive

  • Per-cell and per-region quantitative readouts
  • Cross-sample alignment for cohort analysis
  • Pairs with structural or drug-target readouts on the same volume

Specialised projects

Project-by-project, milestone-driven.

Specialised assay-development work for modalities where we do not yet ship a validated assay off the shelf. Pilots and full builds are set up with agreed upon milestones.

01

ADCs

Project-by-project

Payload distribution at the subcellular scale. Where the warhead actually goes inside individual cells, not approximated by proximity.

What you receive

  • Organelle-level payload localisation
  • Whole-tissue context for biodistribution
  • Quantified per cell, per region
02

LNPs

Developmental

Lipid-nanoparticle uptake and intracellular distribution in intact tissue. Visualising both genetic payload and gene product.

What you receive

  • Organelle-level distribution of LNP and payload
  • Per-cell relative uptake count and spatial maps
  • Distribution across cell types in intact tissue
03

Cell and gene therapies

Developmental

Distribution and retention of RNA therapeutics, gene therapies, and cell therapies in intact tissue.

What you receive

  • 3D distribution mapping in tissue context
  • Per-cell retention metrics
  • Comparisons across dose levels and candidates

Timelines

From samples-in-lab to readout, per modality.

Validated assays

Kidney pathology, antibody biodistribution, multiplex biomarkers

2 to 4 weeks

Biomarker validation

Cohort-level validation, multi-channel readouts

4 to 8 weeks

Specialised assay development

ADCs, LNPs, RNA, cell therapies

Milestone-driven

Tell us about your program. We reply within one business day.

Discuss a project →